Quantitative Fundus Autofluorescence in HCQ Retinopathy.
Adolescent
Adult
Aged
Antirheumatic Agents
/ adverse effects
Child
Electroretinography
Female
Fluorescein Angiography
/ methods
Fundus Oculi
Humans
Hydroxychloroquine
/ adverse effects
Male
Middle Aged
Retinal Diseases
/ chemically induced
Retinal Pigment Epithelium
/ drug effects
Tomography, Optical Coherence
/ methods
Visual Fields
/ drug effects
Young Adult
Journal
Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701
Informations de publication
Date de publication:
01 09 2020
01 09 2020
Historique:
entrez:
25
9
2020
pubmed:
26
9
2020
medline:
1
4
2021
Statut:
ppublish
Résumé
To increase our understanding of the mechanisms underlying hydroxychloroquine (HCQ) retinopathy, analyses by quantitative fundus autofluorescence (qAF) and near-infrared fundus autofluorescence (NIR-AF) were compared to results obtained by recommended screening tests. Thirty-one patients (28 females, 3 males) were evaluated with standard automated perimetry and spectral domain optical coherence tomography (SD-OCT); 28 also had multifocal electroretinography (mfERG). Measurement of short-wavelength fundus autofluorescence (SW-AF) by qAF involved the use of an internal fluorescent reference and intensity measurements in eight concentric segments at 7° to 9° eccentricity. For semiquantitative analysis of NIR-AF, intensities were acquired along a vertical axis through the fovea. Four of 15 high-dose (total dose >1000 g, daily dose >5.0 mg/kg) patients and one of 16 low-dose (total dose <1000 g, daily dose 4.4 mg/kg) patients were diagnosed with HCQ-associated retinopathy based on abnormal 10-2 visual fields, SD-OCT, and SW-AF imaging. Three of the high-dose patients also had abnormal mfERG results. Of the five patients exhibiting retinopathy, two had qAF color-coded images revealing higher intensities inferior, nasal, and lateral to the fovea. The abnormal visual fields also exhibited superior-inferior differences. Mean NIR-AF gray-level intensities were increased in four high-dose patients with no evidence of retinopathy. In two patients with retinopathy, NIR-AF intensity within the parafovea was below the normal range. One high-dose patient (6.25 mg/kg) had only abnormal mfERG results. These findings indicate that screening for HCQ retinopathy should take into consideration superior-inferior differences in susceptibility to HCQ retinopathy.
Identifiants
pubmed: 32976563
pii: 2770837
doi: 10.1167/iovs.61.11.41
pmc: PMC7521180
doi:
Substances chimiques
Antirheumatic Agents
0
Hydroxychloroquine
4QWG6N8QKH
Types de publication
Journal Article
Observational Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
41Subventions
Organisme : NEI NIH HHS
ID : P30 EY019007
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY009076
Pays : United States
Références
Ophthalmology. 2015 Jan;122(1):110-6
pubmed: 25182842
Doc Ophthalmol. 2009 Feb;118(1):69-77
pubmed: 19030905
Clin Ophthalmol. 2010 Oct 21;4:1151-8
pubmed: 21060664
Invest Ophthalmol Vis Sci. 2015 Jul;56(8):5029-39
pubmed: 26230768
Invest Ophthalmol Vis Sci. 2012 Aug 07;53(9):5190-7
pubmed: 22786896
Graefes Arch Clin Exp Ophthalmol. 2005 Oct;243(10):1018-27
pubmed: 15906064
Invest Ophthalmol Vis Sci. 2014 Jul 11;55(9):5643-52
pubmed: 25015357
JAMA Ophthalmol. 2014 Sep;132(9):1105-12
pubmed: 24922444
Invest Ophthalmol Vis Sci. 2013 Jan 17;54(1):585-91
pubmed: 23287793
Retina. 2019 Mar;39(3):473-484
pubmed: 30741731
Invest Ophthalmol Vis Sci. 2014 May 01;55(5):2841-52
pubmed: 24677105
FEBS Lett. 1976 Apr 15;64(1):231-5
pubmed: 5310
APMIS. 2002 Jun;110(6):481-9
pubmed: 12193209
Ophthalmology. 2015 Feb;122(2):345-55
pubmed: 25283059
Invest Ophthalmol Vis Sci. 1996 Apr;37(5):775-82
pubmed: 8603862
J Cell Biol. 1974 Nov;63(2 Pt 1):430-40
pubmed: 4607946
Pharmacogenomics. 2017 Oct;18(15):1393-1400
pubmed: 28975866
Exp Eye Res. 1986 Dec;43(6):915-28
pubmed: 3817032
JAMA Ophthalmol. 2017 Dec 1;135(12):1330-1338
pubmed: 29075777
Br J Ophthalmol. 2012 May;96(5):723-9
pubmed: 22328813
Ophthalmology. 2015 Feb;122(2):356-66
pubmed: 25444344
Doc Ophthalmol. 2015 Feb;130(1):13-23
pubmed: 25502494
Br J Ophthalmol. 2019 Nov;103(11):1600-1604
pubmed: 30819690
JAMA Ophthalmol. 2013 Sep;131(9):1187-97
pubmed: 23887202
Invest Ophthalmol Vis Sci. 2017 Mar 1;58(3):1843-1855
pubmed: 28358950
Lupus. 2018 Sep;27(10):1616-1623
pubmed: 29954281
BMC Ophthalmol. 2015 Mar 06;15:18
pubmed: 25884411
JAMA Ophthalmol. 2014 Dec;132(12):1453-60
pubmed: 25275721
Arch Ophthalmol. 2012 Apr;130(4):461-9
pubmed: 22159170
Graefes Arch Clin Exp Ophthalmol. 1999 Jan;237(1):1-9
pubmed: 9951634
Graefes Arch Clin Exp Ophthalmol. 2016 May;254(5):865-72
pubmed: 26311262
Arch Ophthalmol. 1991 Jan;109(1):84-91
pubmed: 1987955
Curr Eye Res. 2004 Apr;28(4):277-84
pubmed: 15259297
Ophthalmology. 2016 Jun;123(6):1386-94
pubmed: 26992838
J Pharm Sci. 2016 Feb;105(2):884-890
pubmed: 26429523
Clin Exp Ophthalmol. 2010 Aug;38(6):597-604
pubmed: 20456441
Br J Ophthalmol. 2014 Feb;98(2):200-6
pubmed: 24187053
Invest Ophthalmol Vis Sci. 2015 Nov;56(12):7274-85
pubmed: 26551331
Rheumatology (Oxford). 2016 Jun;55(6):957-67
pubmed: 26428520
Invest Ophthalmol Vis Sci. 2015 May;56(5):3159-70
pubmed: 26024099
Invest Ophthalmol Vis Sci. 2019 May 1;60(6):2165-2172
pubmed: 31108547
Ophthalmology. 2015 Jun;122(6):1252-6
pubmed: 25712474
Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3544-50
pubmed: 12882805
Invest Ophthalmol Vis Sci. 2006 Aug;47(8):3531-8
pubmed: 16877425
Am J Ophthalmol. 2007 May;143(5):801-809
pubmed: 17336914
J Opt Soc Am A Opt Image Sci Vis. 2007 Jul;24(7):1842-57
pubmed: 17728807
Retina. 2019 Mar;39(3):492-501
pubmed: 30550532
Invest Ophthalmol Vis Sci. 2013 Aug 21;54(8):5684-93
pubmed: 23860757
Br J Ophthalmol. 2008 Dec;92(12):1653-5
pubmed: 18829634
Invest Ophthalmol Vis Sci. 2014 Mar 13;55(3):1471-82
pubmed: 24526438
J Biol Chem. 2018 Dec 14;293(50):19400-19410
pubmed: 30352873